Strata Critical Medical, Inc. (SRTA) 股票分析

公司概述

Strata Critical Medical, Inc. operates within the healthcare sector, specifically focusing on the medical care facilities industry, by providing time-critical logistics and medical services throughout the United States. The company's operational model is divided into two distinct segments: Logistics and Clinical, with the Logistics segment specifically offering air and ground transportation for human organs and transplant teams. In terms of scale, the enterprise possesses a market capitalization of $359.27M and reported an annual revenue of $197.14M over the trailing twelve months. With an employee count of 327, the company maintains a relatively lean workforce compared to its revenue generation, yet its market cap suggests a valuation that is significantly higher than its revenue base, indicating that the market places a premium on its specialized logistical capabilities and growth potential rather than current profitability.

财务健康

The company reported a revenue of $197.14M and a net income of $-20,066,000, while EBITDA stood at $-5,709,000. The substantial gap between the positive revenue of $197.14M and the negative net income of $-20,066,000 reveals a cost structure where operating expenses and other deductions far exceed gross profit, resulting in a loss for the period. Free cash flow was recorded at $-26,982,624, which indicates that the company is currently burning cash, a situation that limits its financial flexibility for discretionary spending or large-scale internal expansion without external capital injection. Analyzing the margins, the gross margin is 20.9%, while the operating margin is -5.3% and the profit margin is 21.0%, presenting a complex financial picture where high gross profitability is being eroded by significant operating costs, yet the reported profit margin suggests specific accounting adjustments or segment reporting nuances that result in a positive bottom line despite the net income loss. On the balance sheet, total cash holdings of $61.23M provide a liquidity buffer against total debt of $3.31M, supported by a debt-to-equity ratio of 1.19, which suggests a moderately leveraged position where debt levels are elevated but not immediately insolvency-inducing given the cash reserves. The current ratio stands at 6.38, indicating a highly conservative short-term liquidity position where current assets are more than six times current liabilities, ensuring the ability to meet immediate obligations. Furthermore, the return on equity is -8.0% and the return on assets is -2.7%, metrics that reveal that management has not yet generated positive returns on the capital invested or the assets utilized, reflecting the current phase of growth or restructuring rather than mature-stage efficiency.

估值评估

The trailing P/E ratio is N/A and the forward P/E ratio is N/A, meaning that traditional earnings-based valuation metrics are not applicable due to the company's current lack of net income, which prevents a direct comparison with earnings-based multiples for this period. The price-to-book ratio is 0.99, indicating that the market is valuing the company at essentially one dollar for every dollar of its book value, suggesting no significant market premium over the net asset value and implying a valuation grounded in tangible assets. The price-to-sales ratio is 1.82 and the EV/EBITDA is -52.78, which are alternative valuation metrics that suggest the market is pricing the stock based on revenue generation and enterprise value rather than earnings, as the negative EV/EBITDA reflects the negative earnings before interest, taxes, depreciation, and amortization. The 52-week high is $6.02 and the 52-week low is $2.48, and without the specific current share price provided in the facts, the precise percentage deviation cannot be calculated, but the trading range defines the volatility envelope within which the stock has operated over the last year. The beta value is 2.11, which indicates that the stock's price volatility is more than twice that of the broader market, signifying a high-risk profile where price movements are amplified relative to general market shifts.

Growth & Income

The company recorded a revenue growth of 83.5% year-over-year, while the earnings growth rate is N/A due to the negative net income, implying that the rapid expansion in revenue has not yet translated into positive earnings growth. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests its resources back into the business operations and growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is consistent with early-stage or high-growth companies that prioritize expanding their logistics and clinical segments over providing immediate income to investors. In summary, the overall growth and income profile is characterized by aggressive revenue expansion and zero dividend distribution, reflecting a capital allocation strategy focused on scaling operations and achieving future profitability rather than current cash yield.